BioTuesdays

Category - Markets

Unicycive Therapeutics
Markets

Maxim starts Unicycive Therapeutics at buy; PT $3

Maxim Group initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a “buy” rating and price target of $3. The stock closed at $1.07 on March 15. Unicycive is aiming to bring two key assets through clinical...

March 16, 2022
Pardes Biosciences
Markets

SVB Leerink starts Pardes Biosciences at OP; PT $18

SVB Leerink launched coverage of Pardes Biosciences (NASDAQ:PRDS) with an “outperform” rating and $18 price target. The stock closed at $5.54 on March 14. Pardes is a clinical-stage biopharmaceutical company created to...

March 15, 2022
Esperion Therapeutics Logo
Markets

HCW starts Esperion at buy; PT $22

H.C. Wainwright initiated coverage of Esperion Therapeutics (NASDAQ:ESPR) with a “buy” rating and price target of $22. The stock closed at $4.57 on March 9. Esperion is a commercial-stage company focused on development...

March 10, 2022
IDEAYA Biosciences Logo
Markets

Stifel ups IDEAYA Biosciences to buy; PT cut to $20

Stifel upgraded IDEAYA Biosciences (NASDAQ:IDYA) to “buy” from “hold” but cut its price target to $20 from $27, saying the risk/reward around the company’s IDE397 drug candidate is favorable with the stock in the mid-to...

March 10, 2022
Gemini Therapeutics
Markets

SVB Leerink cuts Gemini Therapeutics to MP; PT to $2

SVB Leerink downgraded Gemini Therapeutics (NASDAQ:GMTX) to “market perform” from “outperform” and slashed its price target to $2 from $10, citing an unexpected leadership transition and corporate restructuring. The...

March 3, 2022
CTIBiopharmaLogo
Markets

Brookline ups CTI Biopharma PT to $12 from $7.20

Brookline Capital Markets raised its price target for CTI Biopharma (NASDAQ:CTIC) to $12 from $7.20 after the FDA approved Vonjo in myelofibrosis. The stock closed at $3.10, up $1.20, on volume of 108 million shares on...

March 1, 2022
Arcellx
Markets

WB starts Arcellx at OP; fair value estimate $40

William Blair initiated coverage of Arcellx (NASDAQ:ACLX) with an “outperform” rating and fair value estimate of $40. The stock closed at $16.94 on Feb. 28. Arcellx’s next-generation cell therapy platform is founded on...

March 1, 2022